

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1 to 2. (Cancelled)

3. (Currently Amended) A method of treating and/or preventing a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue, comprising administering ~~Use of an antisecretory protein inducing food made from malted cereals in the manufacture of a food or medical food for the treatment and/or prevention of a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue.~~

4. (Currently Amended) A method of treating and/or preventing a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue, comprising administering a food or medical food comprising ~~Use of an egg yolk with at least 1000 FIL units/ml, of antisecretory protein, in the manufacture of a food or a medical food for the treatment and/or prevention of a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue.~~

5. (Currently Amended) A method of treating and/or preventing a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue, comprising administering a medicament comprising Use of an egg yolk with at least 1000 FIL units/ml, of antiseccretory protein,~~in the manufacture of a medicament for the treatment and/or prevention of a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue.~~

6 to 15. (Cancelled)

16. (Currently Amended) A method of inducing the formation of the antiseccretory protein according to claim 23, comprising administering Use of a food and/or drinking solution made from malted cereal inducing the formation of antiseccretory proteins according to any one of claims 1-14.

17 to 19 (Cancelled)

20. (Currently Amended) A method of propagating, inducing, reducing and/or maintaining the genesis of an isolated stem cell and/or stem cell progeny from any germinal layer *in vitro*, comprising ~~characterised by~~ treating the isolated cell with an antiseccretory protein or an oligo- or polypeptide or derivatives thereof comprising an amino acid sequence of Formula I:

X1-V-C-X2-X3-K-X4-R-X5

(Formula I; SEQ ID NOS: 3-6)

wherein

X1 is I, amino acids nos. 1-35 of SEQ ID NO:2, or is absent

X2 is H, R or K

X3 is S or L

X4 is T or A

X5 is amino acids nos. 43-46 (SEQ ID NO: 3), 43-51 (SEQ ID NO: 4),  
43-80 (SEQ ID NO: 5) or 43-163 (SEQ ID NO: 6) of SEQ ID NO:1, or is absent;  
or a pharmaceutically acceptable salt thereof.

21. (Currently Amended) The A method according to claim 20,  
wherein Formula I has a sequence chosen from one of:

- a) amino acids numbers 35-42 of SEQ ID NO:2,
- b) amino acids numbers 35-46 of SEQ ID NO:2,
- c) amino acids numbers 36-51 of SEQ ID NO:2,
- d) amino acids numbers 36-80 of SEQ ID NO:2,
- e) amino acids numbers 1-80 of SEQ ID NO:2, or
- f) amino acids numbers 1-163 of SEQ ID NO:2

or a pharmaceutically acceptable salt thereof.

22. (Currently Amended) The A method according to claim 20 ~~or~~ 24,  
wherein said isolated cell is chosen from the group comprising epithelial cells,  
fibroblasts, osteogenic cells, macrophages and microglial cells, vascular cells, bone  
cells, chondrocytes, myocardial cells, blood cells, neurons, oligodendrocytes,

astroglial cells, progenitor cells, stem cells and/or cells derived from progenitor cells or stem cells.

23. (Original) A method of treatment and/or prevention of a condition associated with or characterised by a pathological loss and/or gain and/or rescue of nervous tissue, comprising administering to a patient in need thereof an effective amount of an antiseecretory protein, or an oligo- or polypeptide or derivatives thereof comprising an amino acid sequence of Formula I:

X1-V-C-X2-X3-K-X4-R-X5 (Formula I; SEQ ID NOS:3-6)

wherein

X1 is I, amino acids nos. 1-35 of SEQ ID NO:2, or is absent

X2 is H, R or K

X3 is S or L

X4 is T or A

X5 is amino acids nos. 43-46 (SEQ ID NO: 3), 43-51 (SEQ ID NO: 4), 43-80 (SEQ ID NO: 5) or 43-163 (SEQ ID NO: 6) of SEQ ID NO:1, or is absent; or a pharmaceutically acceptable salt thereof.

24. (Currently Amended) The A method according to claim 23, wherein Formula I has a sequence chosen from one of:

- a) amino acids nos. 35-42 of SEQ ID NO:2,
- b) amino acids nos. 35-46 of SEQ ID NO:2,
- c) amino acids nos. 36-51 of SEQ ID NO:2,
- d) amino acids nos. 36-80 of SEQ ID NO:2,

- e) amino acids nos. 1-80 of SEQ ID NO:2, or
- f) amino acids numbers 1-163 of SEQ ID NO:2

or a pharmaceutically acceptable salt thereof.

25. (Currently Amended) The A method according to claim 23 ~~or 24~~, wherein the condition is characterized by displaying a pathological degeneration of, loss of ability and/or loss of control of regeneration of and/or loss of control of regeneration of a differentiated cell and/or tissue, an embryonic stem cell, an adult stem cell, a progenitor cell and/or a cell derived from a stem cell or progenitor cell.

26. (Currently Amended) The A method according to claim 23 ~~any one of claims 23-25~~, wherein the condition is associated with or characterized by a pathological loss and/or gain of cells in the peripheral, autonomic or central nervous system.

27. (Currently Amended) The A method according to claim 23 ~~any one of claims 23-26~~, wherein the condition is associated with or characterized by a pathological loss and/or gain of neural stem cells or neural progenitor cells.

28. (Currently Amended) The A method according to claim 23 ~~any one of claims 23-26~~, wherein the condition is associated with or characterized by a pathological loss and/or gain of oligodendroglial, astroglial, Schwann cells, and/or neuronal cells and/or cell populations.

29. (Currently Amended) The A method according to claim 28, wherein the condition is associated with or characterized by a pathological loss and/or gain of non-cholinergic neuronal cells, cholinergic neuronal cells and/or glial cells, and/or cell populations.

30. (Currently Amended) The A method according to claim 23 ~~any one of claims 23-29~~, wherein the condition is caused by damage to the central nervous system or a defect in the central nervous system.

31. (Currently Amended) The A method according to claim 23 ~~any one of claims 23-29~~, wherein the condition is caused by a traumatic, auto-immune or degenerative disorder.

32. (Currently Amended) The A method according to claim 23 ~~any one of claims 23-29~~, wherein the condition is caused by axonal damage caused by concussion, contusion, axonal damage caused by head trauma, axonal damage caused by small vessel disease in the CNS and/or damage to the spinal cord after disease and/or trauma.

33. (Currently Amended) The A method according to claim 23 ~~any one of claims 23-32~~, wherein said condition is characterised by memory loss.

34. (Currently Amended) The A method according to claim 23 ~~any one of claims 23-33~~, wherein the condition is multiple sclerosis, asphyxia, hypoxic injury, ischemic injury, traumatic injury, Parkinson's disease, Alzheimer's disease, stroke, or demyelinating disorder.

35. (Currently Amended) The A method according to claim 23 ~~any one of claims 23-34~~, wherein the antisecretory protein or the oligo- or polypeptide or derivatives thereof is formulated into a medicament for intravenous infusion, intramuscular injection and/or subcutaneous injection.

36. (Currently Amended) The A method according to claim 21 ~~any one of claims 21-33~~, wherein the antisecretory protein or the oligo- or polypeptide or derivatives thereof is formulated into a medicament so that the active substance will pass into the ventricles and /or other cavities in and/or at a patient's brain when it is administered to said patient.

37. (Currently Amended) The A method according to claim 21 ~~any one of claims 21-34~~, wherein the antisecretory protein or the oligo- or polypeptide or derivatives thereof is formulated into a medicament so that the active substance will pass into the cerebrospinal fluid of a patient when it is administered to said patient.

38. (Presently Amended) A method of propagating, inducing, reducing and/or maintaining the genesis of an isolated stem cell and/or stem cell progeny from any germinal layer from a patient, characterized by:

a) administering an effective amount of an antiseecretory protein or an oligo- or polypeptide or derivatives thereof comprising the amino acid sequence of Formula I as defined in claim ~~1 or claim 2~~ 23 to said patient prior to isolating said cell;

b) propagating said isolated cell *in vitro*;

followed by

c) transplanting said propagated cells into the same or another patient in need thereof.

39. (Presently Amended) A method of propagating, inducing, reducing and/or maintaining the genesis of an isolated stem cell and/or stem cell progeny from any germinal layer from a patient, characterized by:

a) isolating said cell and/or stem cell progeny from the patient;

b) administering an effective amount of an antiseecretory protein or an oligo- or polypeptide or derivatives thereof comprising the amino acid sequence of Formula I as defined in claim ~~1 or claim 2~~ 23 to said isolated cell *in vitro* and propagating said cells; followed by

c) transplanting said propagated cells back into the same or another patient in need thereof.

40. (Currently Amended) The A method according to claim 38 ~~or claim 39~~, wherein said isolated cell is selected from the group consisting of fibroblasts, macrophages, vascular cells, bone cells, chondrocytes, myocardial cells,



blood cells, neurons, oligodendrocytes, astroglial cells, Schwann cells, progenitor cells, stem cells and/or cells derived from progenitor cells or stem cells.

41. (Currently Amended) The method of claim 23, wherein the condition is ~~Use according to any one of claims 1-19, for the treatment of conditions~~ associated with insufficient formation of antiseecretory factors.

42. (Currently Amended) The method of claim 23, wherein the condition is ~~Use according to any one of claims 1-19, for the treatment of conditions~~ associated with insufficient function of the AF receptors and antiseecretory factor binding tissue constituents.